3 citations
,
May 2023 in “Clinical drug investigation” JAK inhibitors for alopecia areata are linked to minor side effects like headache and acne, but not to an increased risk of serious adverse events.
June 2025 in “British Journal of Dermatology” Irish dermatologists urgently need guidelines for using JAK inhibitors in treating alopecia areata.
June 2025 in “British Journal of Dermatology” Dual-targeting therapies like Janus kinase inhibitors may treat both alopecia areata and other immune diseases.
January 2024 in “Revista de la Asociación Colombiana de Dermatología y Cirugía Dermatológica/Revista de la Asociacion Colombiana de Dermatologia y Cirugia Dermatologica” Baricitinib successfully treated severe hair loss.
11 citations
,
February 2022 in “JAAD case reports” Abrocitinib, a JAK inhibitor, may help treat atopic dermatitis and alopecia universalis together.
New drugs, baricitinib and ritlecitinib, are effective for severe alopecia areata.
September 2014 in “SciBX” JAK inhibitors may help treat alopecia areata and promote hair regrowth.
September 2023 in “JAAD case reports” A man developed oral hairy leukoplakia while on baricitinib, a medication for alopecia and arthritis, and doctors should watch for such side effects.
4 citations
,
January 2020 in “PubMed” JAK inhibitors may become the first approved treatment for alopecia areata if they are proven safe and effective.
March 2026 in “Clinical Cosmetic and Investigational Dermatology” Upadacitinib improved multiple immune-related conditions in one patient.
Farudodstat may effectively treat alopecia areata by protecting hair follicles without harmful effects.
June 2024 in “Military medicine” JAK inhibitors like baricitinib and ritlecitinib are effective new treatments for severe alopecia areata.
April 2023 in “Revista colombiana de reumatología” JAK inhibitors like tofacitinib can effectively treat severe alopecia areata.
2 citations
,
March 2026 in “Journal of Dermatological Treatment” JAK inhibitors for alopecia areata have different safety risks, requiring specific monitoring for each drug.
June 2026 in “Frontiers in Immunology” Upadacitinib effectively treated severe atopic dermatitis, vitiligo, and alopecia areata in one patient.
January 2026 in “Skin Health and Disease” Irish dermatologists use JAK inhibitors for alopecia areata but want standardized treatment guidelines.
January 2008 in “Projeto: revista mensal de arquitetura” Targeted cancer drugs can cause skin reactions, so dermatologists must manage these effects.
8 citations
,
July 2019 in “Pure and Applied Chemistry” Some natural compounds from Iris plants can block enzymes related to certain disorders, with a few affecting both targeted enzymes.
6 citations
,
November 2022 in “Journal of autoimmunity” JAK inhibitors like tofacitinib may effectively treat Alopecia Areata.
February 2026 in “Dove Medical Press (Taylor and Francis Group)” Upadacitinib can effectively regrow hair in alopecia areata patients without worsening sarcoidosis.
4 citations
,
October 2023 in “Journal of Medicine and Life” UDCA reduces inflammation and joint damage in rheumatoid arthritis.
63 citations
,
July 2018 in “The journal of investigative dermatology/Journal of investigative dermatology” JAK inhibitors can effectively reverse hair loss in people with alopecia areata.
August 2022 in “Journal of Investigative Dermatology” Baricitinib reduces inflammation and mitochondrial damage in skin cells.
12 citations
,
July 2023 in “Journal of the European Academy of Dermatology and Venereology” Upadacitinib improved Crohn's disease, atopic dermatitis, and alopecia areata in one patient.
February 2026 in “Clinical Cosmetic and Investigational Dermatology” Upadacitinib improves life quality for Alopecia Areata patients without worsening skin issues.
October 2024 in “BMJ Case Reports” Baricitinib effectively treats both rheumatoid arthritis and alopecia areata.
6 citations
,
May 2020 in “JAMA Ophthalmology” Using 5-alpha-reductase inhibitors, drugs for prostate issues and hair loss, may lead to eye abnormalities in men.
April 2023 in “Medicina Clínica (english Edition)”
3 citations
,
February 2022 in “Rheumatology” Baricitinib was effective in treating a patient with dermatomyositis and hair loss.
1 citations
,
May 2017 in “Journal of the American Academy of Dermatology” Oral tofacitinib may be an effective and tolerable treatment for some people with severe alopecia areata.